EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Phase 1

Terminated

Conditions: Refractory or Relapsed Solid Tumors
Lymphoma

Interventions: Drug: Avelumab

First Posted Date: 2018-03-02

Last Posted Date: 2024-06-24

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 21

Registration Number: NCT03451825

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Canada
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇨🇦
Children's Hospital - London Health Sciences Centre, London, Canada

and more 8 locations

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Phase 1

Terminated

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions: Drug: M4112

First Posted Date: 2017-10-11

Last Posted Date: 2020-02-06

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 15

Registration Number: NCT03306420

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
University of TX M.D. Anderson Cancer Center-Investigational Cancer Therapeutics Partner, Houston, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

First Posted Date: 2017-09-15

Last Posted Date: 2018-08-06

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 34

Registration Number: NCT03284970

Locations: 🇺🇸
Neurology Center of New England, Foxboro, Massachusetts, United States

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: M2591 25 mg QD
Drug: M2951 75 mg QD
Drug: M2951 50 mg BID

First Posted Date: 2017-07-28

Last Posted Date: 2020-09-28

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 390

Registration Number: NCT03233230

Locations: 🇺🇦
CI Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporizhzhya, Ukraine
🇿🇦
Naidoo, A, Durban, KwaZulu-Natal, South Africa
🇨🇴
Servimed S.A.S., Bucaramanga, Colombia

and more 93 locations

M3541 in Combination With Radiotherapy in Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: M3541
Radiation: Palliative Radiotherapy (RT)

First Posted Date: 2017-07-21

Last Posted Date: 2023-11-22

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 15

Registration Number: NCT03225105

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

M8891 First in Human in Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Renal Cell Carcinoma
Advanced Solid Tumors

First Posted Date: 2017-05-03

Last Posted Date: 2022-03-11

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 27

Registration Number: NCT03138538

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Sidney Kimmel Cancer Center - Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Smilow Cancer Hospital - Yale, New Haven, Connecticut, United States

and more 4 locations

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Phase 1

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: M3814
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2017-04-17

Last Posted Date: 2020-09-16

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 2

Registration Number: NCT03116971

Locations: 🇪🇸
Research site 4, Madrid, Spain
🇧🇬
Reasearch site 5, Sofia, Bulgaria
🇧🇬
Research site 6, Sofia, Bulgaria

and more 4 locations

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: Avelumab
Drug: Avelumab (Once weekly)
Drug: M9241
Drug: Avelumab (Expansion cohort)
Drug: M9241 (MTD)

First Posted Date: 2016-12-16

Last Posted Date: 2020-12-17

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 52

Registration Number: NCT02994953

Locations: 🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸
Metairie Oncologists, LLC, Metairie, Louisiana, United States
🇮🇹
IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy

and more 30 locations

A Phase II Study of M2951 in SLE

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: M2951
Drug: Placebo

First Posted Date: 2016-11-29

Last Posted Date: 2021-04-12

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 469

Registration Number: NCT02975336

Locations: 🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States

and more 153 locations

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Phase 2

Terminated

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Tecfidera
Drug: Placebo
Drug: Evobrutinib

First Posted Date: 2016-11-29

Last Posted Date: 2024-04-26

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 267

Registration Number: NCT02975349

Locations: 🇺🇦
Research Site, Zaporizhzhia, Ukraine
🇧🇬
Research Site 1, Pleven, Bulgaria
🇧🇬
Research Site 2, Pleven, Bulgaria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy